Generic Name and Formulations:
Gemfibrozil 600mg; scored tabs.
Indications for LOPID:
Type IV and V hyperlipidemias resistant to dietary management, when TG levels are >1000mg/dL and pancreatitis is likely. Reduction in risk of coronary artery disease in certain Type IIb patients with inadequate response to nonpharmacological management and other pharmacologic agents (eg, bile acid sequestrants, nicotinic acid) and have HDL-C levels <35mg/dL, elevated LDL-C and TG. Limitations of use: not indicated for Type I hyperlipoproteinemia with elevated chylomicrons and triglycerides but have normal VLDL. Not indicated for treating patients with low HDL-C as their only lipid abnormality.
1.2g daily in 2 divided doses 30 mins before AM and PM meals.
Hepatic or severe renal dysfunction. Primary biliary cirrhosis. Gallbladder disease. Concomitant simvastatin, repaglinide, dasabuvir, selexipag.
Monitor serum lipids and liver function. Discontinue if lipid response is inadequate after 3 months, or if persistent liver abnormalities or gallstones develop. Obtain blood counts periodically during first 12 months. Evaluate any signs/symptoms of muscle pain, tenderness, or weakness; discontinue if myositis is suspected. Patients with baseline creatinine >2mg/dL: consider alternative therapy. Elderly. Pregnancy. Nursing mothers: not recommended.
See Contraindications. Caution with concomitant anticoagulants; reduce warfarin dose and monitor. May potentiate CYP2C8 substrates (eg, dabrafenib, enzalutamide [seizure risk], loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone) or OATP1B1 substrates (eg, atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan); may need to reduce dose of these substrates. Myopathy, rhabdomyolysis, and acute renal failure with HMG-CoA reductase inhibitors, colchicine (esp. in elderly or renal dysfunction). Separate dosing of bile acid-binding resins (eg, colestipol) by at least 2hrs.
Dyspepsia, abdominal pain, acute appendicitis, atrial fibrillation, gallbladder disease, cholestatic jaundice, blurred vision, hypesthesia, paresthesias, altered taste, dizziness, somnolence, peripheral neuritis, headache, depression, impotence, decreased libido, myopathy, arthralgia, synovitis, abnormal LFTs, blood dyscrasias, angioedema, rash, cataracts.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Tolerability of Novel Long-Acting Injectable Aripiprazole Tested for Bipolar Disorder
- Coping Strategies for Amplified Emotionality May Improve Bipolar Disorder Symptoms
- Link Between Vitamin D Levels and Intracranial Volume in Schizophrenia
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Symptoms of Anxiety, Depression Differ Depending on Gender, Race, Ethnicity
- Examining Whether Adjunctive Glutamatergic Medication Further Eases OCD Symptoms
- FDA Permits Marketing of Brain Stimulation Device for OCD
- Antipsychotics Adversely Affect Adiposity and Insulin Sensitivity in Youths
- Know Before You Go: Practicing Medicine Abroad